GrowGeneration Q3 Earnings Beat Estimates, Revenues Dip 6% Y/Y

GrowGeneration Corp. (GRWG) reported Q2 2026 results: a 3-cent per-share loss, narrower than the Zacks Consensus estimate of a 4-cent loss and versus an 8-cent loss a year earlier. Sales rose 5.5% to $43.2M. Adjusted EBITDA was $0.3M. The company raised full-year adjusted EBITDA guidance to $2–$3M and reaffirmed sales guidance of $162–$168M.

GrowGeneration Corp. reported a third straight quarter of YoY revenue growth, citing a shift to a commercial B2B platform and proprietary brands. Proprietary brand penetration reached 40% ahead of schedule. The company cut store and operating expenses 22% YoY and raised full-year 2026 adjusted EBITDA guidance to $2M-$3M, aided by expected Q3 IEPA tariff refunds. It repurchased 700,000 shares at $1.38.

GrowGeneration (GRWG) reported Q2 2026 revenue of $43.2 million, up 5.5% year over year, with adjusted EBITDA of $0.3 million versus a $1.3 million loss a year earlier. Net loss narrowed to $2.0 million. Gross margin rose to 28.5%. Full-year 2026 guidance: revenue $162-$168 million and adjusted EBITDA $2-$3 million. Cash was $41 million with no debt.

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.

Piper Sandler raised its price target for ExxonMobil (XOM) to $185, citing strong fundamentals, cost savings, and growth in Guyana. XOM's Q2 earnings beat expectations, with high free cash flow and shareholder returns. However, risks include exposure to Middle East conflicts and potential crude price normalization. XOM's stock has risen 30% in 2026, with a 16% upside implied by the new target.